Kiniksa Pharmaceuticals Ltd (KNSA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kiniksa Pharmaceuticals Ltd stock (KNSA) is currently trading at $45.84. Kiniksa Pharmaceuticals Ltd PE ratio is 59.92. Kiniksa Pharmaceuticals Ltd PS ratio (Price-to-Sales) is 5.08. Analyst consensus price target for KNSA is $57.38. WallStSmart rates KNSA as Underperform.
- KNSA PE ratio analysis and historical PE chart
- KNSA PS ratio (Price-to-Sales) history and trend
- KNSA intrinsic value — DCF, Graham Number, EPV models
- KNSA stock price prediction 2025 2026 2027 2028 2029 2030
- KNSA fair value vs current price
- KNSA insider transactions and insider buying
- Is KNSA undervalued or overvalued?
- Kiniksa Pharmaceuticals Ltd financial analysis — revenue, earnings, cash flow
- KNSA Piotroski F-Score and Altman Z-Score
- KNSA analyst price target and Smart Rating
Kiniksa Pharmaceuticals
📊 No data available
Try selecting a different time range
KNSA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Kiniksa Pharmaceuticals Ltd (KNSA)
KNSA trades 28% above its Graham fair value of $35.10, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Kiniksa Pharmaceuticals Ltd (KNSA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, eps growth, institutional own.. Concerns around operating margin and price/book. Fundamentals are solid but monitor weak areas for improvement.
Kiniksa Pharmaceuticals Ltd (KNSA) Key Strengths (4)
Revenue surging 65.00% year-over-year
Earnings per share surging 550.00% year-over-year
103.44% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Kiniksa Pharmaceuticals Ltd (KNSA) Areas to Watch (5)
Very thin margins with limited operational efficiency
Very expensive at 6.2x book value
Premium valuation at 5.1x annual revenue
Thin profit margins with limited profitability
Moderate profitability with room for improvement
Supporting Valuation Data
Kiniksa Pharmaceuticals Ltd (KNSA) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 65.00%, EPS Growth at 550.00%.
The Bear Case
The primary concerns are Operating Margin, Price/Book, Price/Sales. Some valuation metrics including Price/Sales (5.08), Price/Book (6.21) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 11.70%, Operating Margin at 9.78%, Profit Margin at 8.71%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 65.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, EPS Growth) and negatives (Operating Margin, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KNSA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KNSA's Price-to-Sales ratio of 5.08x trades at a deep discount to its historical average of 20.02x (56th percentile). The current valuation is 96% below its historical high of 120.58x set in Feb 2021, and 143% above its historical low of 2.09x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~2.5x, reflecting growing market expectations outpacing revenue growth.
Compare KNSA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Kiniksa Pharmaceuticals Ltd (KNSA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Kiniksa Pharmaceuticals Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 678M with 65% growth year-over-year. Profit margins are thin at 8.7%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 65% YoY, reaching 678M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 53M in free cash flow and 54M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Kiniksa Pharmaceuticals Ltd push profit margins above 15% as the business scales?
Growth sustainability: can Kiniksa Pharmaceuticals Ltd maintain 65%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 59.9x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Kiniksa Pharmaceuticals Ltd.
Bottom Line
Kiniksa Pharmaceuticals Ltd is a high-conviction growth story with revenue accelerating at 65% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 8.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kiniksa Pharmaceuticals Ltd(KNSA)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.